南京医药公告，2025年上半年营业收入279.67亿元，同比增长2.70%。净利润2.91亿元，同比下降 6.44%。 ...

南京医药股份有限公司2025 年半年度报告 公司代码：600713 公司简称：南京医药 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年半年度报告 1 / 171 南京医药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人周建军、主管会计工作负责人孙剑及会计机构负责人（会计主管人员）李菁声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司半年度未进行利润分配。 公司2024年度利润分配方案经公司2025年6月5日召开的2024年年度股东大会审议通过，以实 施权益分派股权登记日登记的总股本1,308,916,414股扣除公司回购专用证券账户中的股份280,951 股后的股份1,308,635,463股为基数，向全体股东每10股派发现金红利1.70元（含税），共计派发现 金红 ...

| 证券简称：南京医药 | 编号：ls2025-112 | | --- | --- | | 证券代码：600713 | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于公司募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意南京医药 股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕 1736 号）核准，公司向不特定对象发行可转换公司债券 10,814,910 张，每张面 值为人民币 100 元（人民币，下同），募集资金总额为人民币 1,081,491,000.00 元，扣除与发行有关的费用人民币 12,450,077.69 元（不含增值税），募集资金净 额为人民币 1,069,040,922.31 元。 上述募集资金已于 2024 年 12 月 31 日到账，毕马威华振会计师事务所（特 殊普通合伙）对本次募集资金到位情况进 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

证券代码：600713 证券简称：南京医药 编号：ls2025-109 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于挂牌出租南京市秦淮区延龄巷27号房地产的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）在南京市公共资源交易中心以公开挂牌方式出租权属于公司 的南京市秦淮区延龄巷27号房地产（以下简称"标的资产"）。 2025年8月20日，公司收到南京市公共资 源交易中心《国有企业房产出租成交确认书》，确认本次挂牌承租方为万谷企业管理集团有限公司（以 下简称"万谷公司"），现将具体进展情况公告如下： 一、挂牌出租标的资产的审议程序 万谷企业管理集团有限公司 住所：南京市雨花台区小行路16号 法定代表人：金平 注册资本：6,666.67万元 2025年6月23-25日，公司第十届董事会临时会议审议通过《关于公司公开挂牌出租南京市秦淮区延龄巷 27号房地产的议案》。董事会同意公司公开挂牌出租标的资产，挂牌出租起始年租金租赁价格为711.55 万元/年（人民币 ...

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its third short-term financing bond for 2024, with a total issuance amount of 50 million yuan [1] - The bond, named "24 Nanjing Pharmaceutical SCP003," has an interest rate of 1.8% and a maturity period of 269 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be approximately 50.66329 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the Interbank Market Clearing House before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the Interbank Market Clearing House of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

证券代码：600713 证券简称：南京医药 编号：ls2025-108 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2025 年度第二期超短期融资券（债券简称：25 南京医药 SCP002，债券代码：012580666）兑付工作的顺利进行，现将有关事宜 公告如下： 一、本期债券基本情况 发行人名称 南京医药股份有限公司 超短期融资券 | 债项简称 | 25 南京医药 | SCP002 | | --- | --- | --- | | 债项代码 | 012580666 | | | 发行金额（万元） | 50,000 | | | 起息日 | 2025-03-17 | | | 发行期限 | 179 天 | | | 债项余额（万元） | 50,000 | | | 最新评级情况 | / | | | 偿还类别 | 本息兑付 | | | 本计息期债项利率 | 1.94% | | | 本息兑付日 | 2025-09-12 | | | 本期应偿付本息 ...

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

证券代码：600713 证券简称：南京医药 编号：ls2025-109 2025 年 6 月 23-25 日，公司第十届董事会临时会议审议通过《关于公司公开 挂牌出租南京市秦淮区延龄巷 27 号房地产的议案》。董事会同意公司公开挂牌 出租标的资产，挂牌出租起始年租金租赁价格为 711.55 万元/年（人民币，下同）。 出租总面积 13,325.11 平方米（以实际可租赁面积为准），租赁期限为 13 年（156 个月，免租期为 6 个月，租赁期前三年均摊）。租金按季支付，租金单价前三年 不变，第四年起开始递增，每三年在上一年租金的基础上递增 5%，租赁期的租 金总收入预计为 9,709.73 万元。最终成交价格及承租人根据公开挂牌结果予以确 定。董事会同时授权公司经营层具体办理上述资产挂牌出租相关事宜。详情请见 公司于 2025 年 6 月 26 日对外披露的编号为 ls2025-093 之《南京医药股份有限公 司关于公开挂牌出租南京市秦淮区延龄巷 27 号房地产的公告》。 二、挂牌进展情况 2025 年 7 月 16 日至 2025 年 7 月 29 日，标的资产在南京市公共资源交易中 心挂牌，公开征集承租人 ...